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TOLERANCE INDUCTION BY DONOR CHIMERISM AFTER HEMATOPOI-
ETIC CELL TRANSPLANTATION FROM THE SAME HAPLOIDENTICAL FA-
MILIAL DONOR IN A LIVER TRANSPLANT RECIPIENT
Kim, S.-D.1, Lee, J.-H.1, Lee, J.-H.1, Kim, D.-Y.1, Choi, Y.1, Lee, S.-
G.2, Hwang, S.2, Lee, K.-H.1 1Asan Medical Center, Seoul, Korea;
2Asan Medical Center, Seoul, Korea
Despite recent improvement of short term results in organ trans-
plantation, long term outcomes are still limited by serious side effects
of immunosuppressive agents. Induction of immune tolerance re-
mains an important goal of liver transplantation. Donor chimerism
has been believed to be associated with donor specific tolerance
and allograft acceptance. We report a liver transplant recipient
with successful withdrawal of immunosuppressive treatment after al-
logeneic hematopoietic cell transplantation (HCT) from the same
haploidentical familial donor. A 51-year-old gentleman underwent
allogeneic HCT from his son for the treatment of secondary acute
myeloid leukemia with resistant disease despite cytarabine plus dau-
norubicin induction chemotherapy. Twenty months prior to HCT,
he received liver transplantation from the same donor for hepatitis B
virus associated fulminant hepatic failure, which was developed after
the completion of chemotherapy (3 cycles of R-CHOP regimen) and
radiotherapy (3,060 cGy) for the treatment of non-Hodgkin lym-
phoma. Tacrolimus and mycophenolate mofetile were given for
the prevention of rejection of donor liver until HCT. The immuno-
suppression was changed to cyclosporine when the conditioning
therapy, consisted of busulfan (6.4 mg/kg), fludarabine (180 mg/
kg) and anti-thymocyte globulin (12 mg/kg), was administered for
HCT. Neutrophil engraftment was achieved 13 days after HCT
and complete donor chimerism was documented by STR-PCR anal-
ysis 15 days after HCT. Cyclosporine was discontinued 36 days after
HCT because EBV-associated post-transplant lymphoproliferative
disorder (PTLD) was found in stomach. The PTLD was well con-
trolled with rituximab and donor lymphocyte infusion. Thereafter,
he was well without any evidence of leukemia relapse, graft-versus-
host disease, or liver rejection. Engraftment and donor chimerism
was stable. However, he died of RSV pneumonia 11 months after
HCT. Our case shows that immune tolerance can be induced in or-
gan transplantation by donor chimerism following allogeneic HCT.468
NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANT FOR INHERITED AUTOSOMAL DOMINANT DISEASE DUE
TO MUTATIONS IN THE PSTIPI GENE (PAPA SYNDROME). AN OVERVIEW
OF NURSING CONSIDERATIONS IN PATIENTS UNDERGOING
TRANSPLANTATION
Rush, J.A. Texas Oncology-Sammons Cancer Center, Dallas, TX
Hematopoietic stem cell transplantation has been used as an effec-
tive therapy for selected autosomal disease providing patients pro-
longed long-term survival and optimizing quality of life. PAPA
syndrome is an autosomal dominant disease derived from the muta-
tions in the PSTPIPI gene. Furthermore, the PSTPIPI gene is ex-
pressed in hematopoietic cells and encodes a protein that binds to
pyrin and controls the production of interleukin-1. Themain clinical
manifestations of PAPA syndrome are pyogenic sterile arthritis, pyo-
derma gangrenosum and cystic acne. Nursing considerations specific
to PAPA syndrome for individuals during hematopoietic stem cell
transplants entails many significant dynamics for individual nurses
during the inpatient stay requiring skills to care for not only the pa-
tient physically, but emotionally. A survey was composed during pa-
tient care and distributed within the inpatient unit to all nurses who
had direct care contact with the patient who presented with PAPA
syndrome. The data reflected a retrospective view of significant ele-
ments of care nurses found challenging as well as, identifying educa-
tional needs for the nurses who cared for the patient with the
diagnosis of PAPA syndrome. Bone marrow transplant nurses play
a vital role in managing the care of patients with PAPA syndrome
making it imperative that the nurse have a strong knowledge of the
patients’ unique considerations. Therefore, through close observa-
tion and monitoring the nursing is able to identify adverse effects
or complications that may develop pre, during and post transplant.469
ASSESSING THE ‘‘6TH VITAL SIGN’’: DEVELOPMENT OF AN INPATIENT
DISTRESS SCREENING TOOL FOR BONE MARROW TRANSPLANT PA-
TIENTS
Sontag, L. Jewish Hospital/Mercy Health Partners, Cincinnati, OH
The identification of distress as the ‘‘6th vital sign’’ poses a challenge
to the inpatient treatment team to assess and address the physical, emo-
tional, economic, social and spiritual toll on bone marrow transplanta-
tion (BMT) patients. BMT requires long weeks of inpatient hospital
stays and arduous treatment protocols, and many studies have demon-
strated that it has a profound impact on the quality of life of both pa-
tients and their families. Screening for distress in an inpatient BMT
unit must address the unique concerns of BMT patients.
An 8 week pilot study was performed on a 23 bed BMT inpatient
unit to assess the efficacy of using theNCCNDistress Thermometer
and Patient Problem List with a BMT population. Patients were
screened weekly and identified areas of distress were addressed. Sev-
eral drawbacks to using the DT/PPL emerged through the pilot and
a new tool was developed as a brief, comprehensive, face valid screen-
ing instrument. The new measure focuses on practical, emotional,
family and physical issues as well as spiritual concerns and uses a likert
rating scale to assess degree of distress in each area. Patients and
medical, social work and psychology staff gave input into the items
included and excluded in the newmeasure. The newBMTUDistress
Screening Measure takes patients about 3-5 minutes to fill out, can
be read aloud easily to less able or illiterate patients and the results
are easily understood ‘‘at a glance’’ by medical staff. The measure
then becomes potentially useful charted data to flag patients in
need of intervention by appropriate staff (social work, psychologist,
chaplain, financial counselor) and to assess the progress of interven-
tions throughout the trajectory of the BMT inpatient stay.
This inpatient-specific BMTU Distress Screening Measure is in
process of validation using the NCCN-DT, the Hospital Anxiety
& Depression Scale, the brief Religious Coping Measure, the Pear-
lin-Schooler Mastery Scale, and the Meaning of Illness Scale.
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COMMERCIAL RUO REAGENTS AND SOFTWARE FOR EARLY DETECTION
OF MIXED CHIMERISM
Bost, D.A., McLaughlin, I.J., Beckert, S. Celera, Alameda, CA
Assessing engraftment kinetics and monitoring potential rejec-
tion/relapse events requires assay systems which not only have the
ability to distinguish closely-matched individuals, but also accurately
and precisely determine the relative levels of host and recipient cells
present in mixtures of the two. The current standard practice – use of
forensic identity kits – fulfills the need for finding unique genetic
markers between individuals, but its ability to be applied in a quanti-
tative fashion is extremely limited. Use of qPCR assays and software
designed specifically for this application allow for facile quantifica-
tion of minute amounts of minor components in a mixture, while
also reducing workflow and analysis burdens. This approach expands
the linear dynamic range over which increasing mixed chimerism
may be monitored, effectively increasing the probability of detecting
adverse transplant events earlier.
To address the limitation of quantifying the DNA contributors in
a chimeric DNA sample, we have developed a panel of 34 real-time
PCR research assays. The probability of finding at least one informa-
tivemarker in the panel of 34 loci is. 99.9% in unrelated individuals
(Caucasian, African, Japanese, Amerindian populations). The prob-
ability of finding at least one informative marker in sibs is greater
than 99%, 98%, 98% and 97% for European Caucasian, Japanese,
Amerindian and African populations, respectively.
Each of the 34 research assays was tested using simulatedDNAmix-
tures at 0.05%, 0.1%, 0.2% and 0.4%minor component for 250 ng of
input genomic DNA. Each assay was able to detect the 0.05% minor
component mixture. The limitation at this low sensitivity is input
copy number. In addition, each of the assays in the panel was able to
detect, with statistical significance (p\ 0.05), the 2-fold change be-
tween the 0.1% and 0.2%minor componentmixtures.Multiple assays
tested on the same mixtures gave highly reproducible results.
The ability to detect early changes in increasing mixed chimerism,
with greater accuracy and precision, allows for more effective
research into the potential benefits of earlier detection of clinically
significant events, such as relapse.
